James A Fletcher
Overview
Explore the profile of James A Fletcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shanmugasundaram K, Ahmed E, Miao X, Kulasinghe A, Fletcher J, Monkman J, et al.
ACS Sens
. 2024 Jun;
9(6):3009-3016.
PMID: 38836608
Immune checkpoint inhibitors (ICIs) targeting programmed cell death ligand 1 (PD-L1), or its receptor, PD-1 have improved survival in patients with non-small-cell lung cancer (NSCLC). Assessment of PD-L1 expression requires...
2.
Fletcher J, Mullally W, Ladwa R, OByrne K
JTO Clin Res Rep
. 2024 Feb;
5(2):100591.
PMID: 38357093
gene rearrangements are detected in approximately 3% to 5% of NSCLC. tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in -rearranged NSCLC; however, they have been associated...
3.
Fletcher J, Logan B, Reid N, Gordon E, Ladwa R, Hubbard R
BMC Cancer
. 2023 Jun;
23(1):498.
PMID: 37268891
Aims: The frailty index (FI) is one way in which frailty can be quantified. While it is measured as a continuous variable, various cut-off points have been used to categorise...
4.
Fletcher J, Fox S, Reid N, Hubbard R, Ladwa R
Cancer Treat Res Commun
. 2022 Oct;
33:100652.
PMID: 36306604
Background: Frailty is prevalent in older adults with lung cancer, however the impact of frailty in this population is not well understood. The aim of this review was to evaluate...